2% Lidocaine Plus 0.5% Bupivacaine Versus 0.5% Bupivacaine in Brachial Block for Creation of Arteriovenous (AV) Fistula

NCT ID: NCT00993746

Last Updated: 2010-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Will the technique of adding lidocaine to bupivacaine fasten the onset of bupivacaine alone for infraclavicular brachial plexus block in end-stage renal disease (ESRD) patient?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infraclavicular Brachial Plexus Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bupivacaine plus lidocaine

Group 1: bupivacaine 20 ml plus lidocaine 10 ml

Group Type ACTIVE_COMPARATOR

Bupivacaine plus lidocaine

Intervention Type DRUG

Bupivacaine 20 ml plus lidocaine 10 ml

Bupivacaine alone

Group 2: bupivacaine 30 ml

Group Type EXPERIMENTAL

Bupivacaine 30 ml

Intervention Type DRUG

Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine plus lidocaine

Bupivacaine 20 ml plus lidocaine 10 ml

Intervention Type DRUG

Bupivacaine 30 ml

Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Marcaine Xylocaine lidocaine, marcaine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ESRD patient for AVF procedure
* age \>17 year
* BMI 20-35 kg/m2
* communicable

Exclusion Criteria

* BMI \> 35 kg/m2 BMI \< 20 kg/m2 หรือ BW \< 35 kg
* History of allergy to local anesthetic drugs
* Pre-operative neurological deficit, Neuromuscular disorder หรือ old CVA
* Psychiatric disorder
* Coagulation disorder
* Uncontrolled seizure
* Pregnant and lactating women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mahidol University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahidol University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Orawan Pongrawewan, MD

Role: PRINCIPAL_INVESTIGATOR

Siriraj Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of anesthesiology Siriraj Hospital Mahidol University

Bangkok, , Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Orawan Pongraweewan, MD,FRCA

Role: CONTACT

6681-4317599

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

si433/2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.